DexCom's growth rate has been declining over multiple periods. The company expects as little as 1% organic growth for the current quarter. Investors may see this as proof that GLP-1 drugs are ...

At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long run.

Welcome to the DexCom First Quarter 2025 Earnings Release Conference Call. My name is Louella, and I will be your operator for today's call. [Operator Instructions] As a reminder, the conference is ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

Dexcom’s first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University’s ...

We recently published 10 Stocks Bleeding Early. DexCom, Inc. (NASDAQ:DXCM) is one of the worst-performing stocks on Monday. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to ...

Dexcom has won a nod from FDA for the G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. With this clearance, the San Diego, CA-based company continues to ...